NICE Endorses Dupilumab for Eosinophilic COPD T...

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance re...
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...